PositiveReview/Other2021
From a Designer Drug to the Discovery of Selective Cannabinoid Type 2 Receptor Agonists with Favorable Pharmacokinetic Profiles for the Treatment of Systemic Sclerosis
Classification Results
AI Classification
PositiveFine-tuned Classification
Positive